CDK2 and breast cancer: Through integrated proteomics and phosphoproteomics analysis of cisplatin-sensitive (T24S) and cisplatin-resistant (T24R) T24 human BC cell lines, CDK2 was identified as a potential chemoresistance biomarker in BC.88